



## Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value

Thursday • November 14, 2019 • 10:00 am to 4:00 pm

Stephen Robert '62 Campus Center, Petteruti Lounge and Kasper Multipurpose Room,  
75 Waterman Street, Providence, RI, 02912

Time	Activity
9:30 am – 10:00 am	Registration
10:00 am – 10:15 am	<b>Meeting Convened and Opening Remarks</b> Steven D. Pearson, MD, MSc, President, ICER
10:15 am – 11:20 am	<b>Presentation of the Evidence and Economic Modeling</b> <ul style="list-style-type: none"> <li>David Rind, MD, MSc, Chief Medical Officer, ICER</li> <li>Greg Guzauskas, PhD, MSPH, Research Scientist, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy University of Washington</li> </ul>
11:20 am—11:50 am	<b>Manufacturer Comments and Discussion</b>
11:50 am—12:00 pm	<b>Public Comments and Discussion</b>
12:00 pm—1:00 pm	Lunch
1:00 pm—2:15 pm	<b>New England CEPAC Panel Vote on Clinical Effectiveness and Value</b>
2:15 pm—2:30 pm	Break
2:30 pm—3:45 pm	<b>Policy Roundtable Discussion</b>
3:45 pm—4:00 pm	<b>Reflections from New England CEPAC Panel</b>
4:00 pm	<b>Meeting Adjourned</b>

ICER Staff and Consultants	
<b>Pam Bradt, MD, MPH,*</b> Chief Scientific Officer, ICER	<b>Ryan Hansen, PhD, PharmD,*</b> Assistant Professor, Department of Pharmacy, School of Pharmacy, University of Washington
<b>Eric Borrelli, PharmD, MBA,*</b> Evidence Synthesis Intern, ICER	<b>Catherine Koola, MPH,*</b> Program Manager, ICER
<b>Rick Chapman, PhD, MS,*</b> Director of Health Economics, ICER	<b>Steve Pearson MD, MSc,*</b> President, ICER
<b>Katherine Fazioli, BS,*</b> Research Lead, ICER	<b>Michelle Poulin, BA*</b> Senior Program and Event Coordinator, ICER
<b>Greg Guzauskas, MSPH, PhD,*</b> Research Scientist, Department of Pharmacy, School of Pharmacy, University of Washington	<b>David Rind, MD, MSc,*</b> Chief Medical Officer, ICER

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

**Participating Members of New England CEPAC**

<p><b>Robert Aseltine Jr, PhD*</b> Professor and Chair, Division of Behavioral Sciences and Community Health, UCONN Health</p>	<p><b>Stephanie Nichols, PharmD, BCPS, BCPP, FCCP*</b> Associate Professor Pharmacy Practice, University of New England College of Pharmacy</p>
<p><b>Marthe Gold, MD, MPH*</b> Senior Scholar, New York Academy of Medicine</p>	<p><b>Leslie Ochs, PharmD, PhD, MSPH*</b> Associate Professor of Social and Administrative Pharmacy, University of New England College of Pharmacy</p>
<p><b>Claudio Gualtieri, JD*</b> Advisor, Center to Champion Nursing in America, AARP</p>	<p><b>Brian O’Sullivan*</b> Professor of Pediatrics, Geisel School of Medicine at Dartmouth College</p>
<p><b>Stephen Kogut, PhD, MBA, RPh*</b> Professor of Pharmacy Practice, University of Rhode Island College of Pharmacy</p>	<p><b>Jason Schwartz, PhD*</b> Assistant Professor, Department of Health Policy and Management, Yale School of Public Health</p>
<p><b>Greg Low, RPh, PhD*</b> Program Director, MGPO Pharmacy Quality and Utilization Program</p>	<p><b>Jason Wasfy, MD, MPhil*</b> Director, Quality and Outcomes Research, Massachusetts General Hospital Heart Center</p>
<p><b>Eleftherios Mylonakis, MD, PhD, FIDSA*</b> Chief of the Infectious Diseases Division and Dean’s Professor of Medicine, Warren Alpert Medical School of Brown University</p>	<p><b>Edward Westrick, MD, PhD*</b> Primary Care Physician, Assistant Medical Director, Comprehensive Community Action Program</p>

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member’s household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<b>Jeff Casberg, MS, RPh</b> , Director of Clinical Pharmacy, IPD Analytics	Owns stock shares in Anthem, Cigna, CVS, and McKesson.
<b>Bonnie Donato, MA, PhD</b> , Executive Director of Primary Care, Health Economics, and Outcomes Research, Boehringer Ingelheim	Full-time employee of Boehringer Ingelheim.
<b>Todd Hobbs, MD</b> , Vice President, Chief Medical Officer of North America, Novo Nordisk	Full-time employee of Novo Nordisk.
<b>Bill McQuade, DSc, MPH</b> , Senior Health Policy Analyst, Rhode Island Executive Office of Health and Human Services, Office of Medicaid	No conflicts of interest to disclose.
<b>Joanna Mitri, MD, MS</b> , Staff Endocrinologist, Joslin Diabetes Center	Received research support and non-branded speaking support from the National Dairy Council, as well as research support from the National Institutes of Health, Kowa Pharmaceutical Co., and the Juvenile Diabetes Research Foundation.
<b>Lisa Murphy, MD, DPhil</b> , Chief, Division of Endocrinology and Metabolism, San Francisco General Hospital, University of California, San Francisco	No conflicts of interest to disclose.
<b>David Strutton, PhD</b> , Vice President, Global Pharmaceuticals & Policy Research, Center for Observational and Real-World Evidence, Merck	Full-time employee of Merck.
<b>Susan Weiner, MS, RDN, CDE, FADE</b> , Scientific Council Member, Beyond Type 2	No conflicts of interest to disclose.